CN101511383A - Wnt5a用于抑制瘢痕形成的应用 - Google Patents

Wnt5a用于抑制瘢痕形成的应用 Download PDF

Info

Publication number
CN101511383A
CN101511383A CNA2007800318493A CN200780031849A CN101511383A CN 101511383 A CN101511383 A CN 101511383A CN A2007800318493 A CNA2007800318493 A CN A2007800318493A CN 200780031849 A CN200780031849 A CN 200780031849A CN 101511383 A CN101511383 A CN 101511383A
Authority
CN
China
Prior art keywords
wnt5a
scarring
derivative
wound
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800318493A
Other languages
English (en)
Chinese (zh)
Inventor
马克·威廉·詹姆斯·弗格森
修·杰勒德·莱弗蒂
尼克·奥克莱斯顿
沙伦·奥凯恩
凯丽·尼尔德
尼克·格德斯宾克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of CN101511383A publication Critical patent/CN101511383A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007800318493A 2006-06-30 2007-06-29 Wnt5a用于抑制瘢痕形成的应用 Pending CN101511383A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0613031.4A GB0613031D0 (en) 2006-06-30 2006-06-30 Medicaments
GB0613031.4 2006-06-30

Publications (1)

Publication Number Publication Date
CN101511383A true CN101511383A (zh) 2009-08-19

Family

ID=36888398

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800318493A Pending CN101511383A (zh) 2006-06-30 2007-06-29 Wnt5a用于抑制瘢痕形成的应用

Country Status (11)

Country Link
US (1) US20100137201A1 (OSRAM)
EP (1) EP2046364A2 (OSRAM)
JP (1) JP2009542609A (OSRAM)
CN (1) CN101511383A (OSRAM)
AU (1) AU2007263593A1 (OSRAM)
BR (1) BRPI0713807A2 (OSRAM)
CA (1) CA2656965A1 (OSRAM)
GB (1) GB0613031D0 (OSRAM)
MX (1) MX2008016520A (OSRAM)
WO (1) WO2008001113A2 (OSRAM)
ZA (1) ZA200900708B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117159463A (zh) * 2017-08-20 2023-12-05 加州大学董事会 治疗青光眼的Wnt5a的调节

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0702930D0 (en) * 2007-02-15 2007-03-28 Renovo Ltd Medicaments and methods for inhibition of scarring
WO2009047330A1 (en) * 2007-10-12 2009-04-16 Universite Louis Pasteur Use of wnt5a for treating or preventing obesity and atherosclerosis
CN101790221B (zh) * 2009-01-22 2015-05-06 中兴通讯股份有限公司 家用基站切换时网络接入控制方法及系统
EP2226080A1 (en) * 2009-03-05 2010-09-08 Universiteit Maastricht Antagonistic peptides for frizzled-1 and frizzled-2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485972B1 (en) * 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
CA2408701A1 (en) * 2000-05-12 2001-11-22 University Of Utah Research Foundation Compositions and methods for tissue dedifferentiation and regeneration
US20040087016A1 (en) * 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
JP2004533829A (ja) * 2001-04-06 2004-11-11 インサイト・ゲノミックス・インコーポレイテッド 細胞成長、分化および細胞死関連タンパク質
US20050037011A1 (en) * 2002-11-21 2005-02-17 Jones Stephen N. Diagnosing and treating hematopoietic cancers
US7374760B2 (en) * 2003-05-15 2008-05-20 The University Of Chicago Methods and compositions for nerve regeneration
WO2005118782A2 (en) * 2004-04-16 2005-12-15 Hydra Biosciences, Inc. Methods of promoting cardiac cell proliferation
EP2322600B1 (en) * 2004-08-30 2012-03-21 Theregen, Inc. Cultured three dimensional tissues and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117159463A (zh) * 2017-08-20 2023-12-05 加州大学董事会 治疗青光眼的Wnt5a的调节

Also Published As

Publication number Publication date
WO2008001113A2 (en) 2008-01-03
EP2046364A2 (en) 2009-04-15
WO2008001113A3 (en) 2008-03-13
US20100137201A1 (en) 2010-06-03
GB0613031D0 (en) 2006-08-09
CA2656965A1 (en) 2008-01-03
AU2007263593A1 (en) 2008-01-03
BRPI0713807A2 (pt) 2012-11-06
MX2008016520A (es) 2009-04-01
ZA200900708B (en) 2010-05-26
JP2009542609A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
US20100266532A1 (en) Methods for inhibiting scarring
US20120238505A1 (en) Medicaments
CN101511383A (zh) Wnt5a用于抑制瘢痕形成的应用
US20110212897A1 (en) Wnt3a for inhibition of scarring
US20100261659A1 (en) Secreted frizzled related protein 3 for use in the inhibition of scarring
CA2726442A1 (en) Medicaments and methods for inhibition of scarring
JP2010535184A (ja) 非眼瘢痕の抑制に使用できる薬剤および方法
CA2733797A1 (en) Methods for inhibition of scarring
CA2733794A1 (en) Methods for the inhibition of scarring
HK1158509A (en) Il-10 related peptides for wound healing
HK1105366B (en) Il-10 related peptides for wound healing

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090819